Last reviewed · How we verify
Bicalutamide Oral Product
Bicalutamide is a nonsteroidal antiandrogen that inhibits the action of androgens.
Bicalutamide is a nonsteroidal antiandrogen that inhibits the action of androgens. Used for Metastatic prostate cancer, Early stage prostate cancer.
At a glance
| Generic name | Bicalutamide Oral Product |
|---|---|
| Sponsor | Gynaecologisch Oncologisch Centrum Zuid |
| Drug class | Nonsteroidal antiandrogen |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to androgen receptors in cells, thereby blocking the effects of androgens such as testosterone and dihydrotestosterone. This can help slow the growth of prostate cancer cells.
Approved indications
- Metastatic prostate cancer
- Early stage prostate cancer
Common side effects
- Hot flashes
- Impotence
- Breast tenderness
- Fatigue
- Diarrhea
Key clinical trials
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (PHASE2, PHASE3)
- Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy (NA)
- Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer (PHASE1)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer (PHASE4)
- Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (PHASE3)
- Drug-Drug Interaction Study in Trans Women Living With HIV (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bicalutamide Oral Product CI brief — competitive landscape report
- Bicalutamide Oral Product updates RSS · CI watch RSS
- Gynaecologisch Oncologisch Centrum Zuid portfolio CI